Internal Server Error

Inosan - About the company

Inosan is an unfunded company based in Madrid (Spain), founded in 2012 by Juan Lopez de Silanes Blanco. It operates as an Antivenin and antitoxin development company. Inosan has not raised any funding yet. The company has 438 active competitors, including 142 funded and 116 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.

Company Details

Inosan is a Spanish antivenin and antitoxin development company. Their antivenins have a high specificity and a low number of FAB fragments. Their antivenin are classified geographically so that they neutralize venoms of species of snakes, scorpions or spiders distributed in a specific geographical area (North Africa-Middle East, EurAsia, South America, etc.) They develop antitoxins for rabies, botulism, tetanus and diphtheria.
Phone Number
+34 **********
Key Metrics
Founded Year
2012
Location
Madrid, Spain
Stage
Unfunded
Ranked
Employee Count
27 as on Jul 31, 2026
Similar Companies
Sign up to download Inosan's company profile

Inosan's funding and investors

Inosan has not raised any funding rounds yet.

Inosan's founders and board of directors

Founder? Claim Profile
The founders of Inosan is Juan Lopez de Silanes Blanco.
Here are the details of Inosan's key team members:

Inosan's employee count trend

Inosan has 27 employees as of Jul 26. Here is Inosan's employee count trend over the years:
Employee count trend for Inosan
lockUncover Inosan's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Inosan's Competitors and alternates

Top competitors of Inosan include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Inosan, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for BeiGene
BeiGene
2010, Cambridge (United States), Public
Developer of targeted and immune-oncology drugs against cancer
$172M
81/100
2nd
Logo for Biogen
Biogen
1978, Cambridge (United States), Public
Developer of therapies for neurodegenerative and immunology disorders
$80M
78/100
3rd
Logo for argenx
argenx
2008, Ghent (Belgium), Public
Developer of antibody-based drugs to treat autoimmune diseases and cancer
$61.9M
75/100
4th
Logo for C4 Therapeutics
C4 Therapeutics
2016, Cambridge (United States), Public
Developer of small molecule drugs for treating cancer
$223M
71/100
5th
Logo for Abcellera Biologics
Abcellera Biologics
2012, Vancouver (Canada), Public
AI-enabled platform for antibodies discovery
$115M
71/100
6th
Logo for BioNTech
BioNTech
2008, Mainz (Germany), Public
Developer of immunotherapeutics for the treatment of cancer and other diseases
$861M
69/100
7th
Logo for Immunocore
Immunocore
2008, Abingdon (United Kingdom), Public
Developer of bispecific T cell receptor therapies for human diseases
$601M
69/100
8th
Logo for ADMA Biologics
ADMA Biologics
2005, Ramsey (United States), Public
Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases
$17.6M
68/100
9th
Logo for Nimbus Therapeutics
Nimbus Therapeutics
2009, Cambridge (United States), Series F
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases
$637M
68/100
10th
Logo for DBV Technologies
DBV Technologies
2002, Bagneux (France), Public
Developer of products for the treatment of various kinds of food allergies
$68.9M
68/100
288th
Logo for Inosan
Inosan
2012, Madrid (Spain), Unfunded
Antivenin and antitoxin development company
-
-
29/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Inosan's competitors? Click here to see the top ones

Inosan's Investments and acquisitions

Inosan has made no investments or acquisitions yet.

Reports related to Inosan

Here is the latest report on Inosan's sector:

FAQs about Inosan

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford